[36] found that NSCLC patients exhibiting reduced miR-935 expression had a poorer prognosis, with this miRNA functioning by suppressing AKT pathway activation and the epithelial-mesenchymal transition of these tumor cells, impairing their in vivo growth. This evidence concerns the gene AKT1 and neoplasm.